Splitomicin is a cell-permeable lactone that acts as an inhibitor of sirtuins 1 and 2 (SIRT1, SIRT2); sirtuins are considered class III histone deacetylases (HDACs). Splitomicin displays anti-inflammatory, antioxidative, and antithrombotic activities. In vitro, splitomicin promotes translocation of FOXO3a, decreasing cell motility and enhancing activity of paclitaxel. In neutrophils, splitomicin decreases production of superoxide anions, suppresses activation of ERK, and increases levels of cAMP. In other cellular models, this compound inhibits thrombin-induced platelet aggregation, preventing increases in thromboxane B2 (TxB2) and release of intracellular Ca2+; this compound may also inhibit phosphodiesterases. Splitomicin also alters RNA splicing activity.